Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Dec 13, 2022 12:52pm
126 Views
Post# 35168829

RE:RE:Time is running out...

RE:RE:Time is running out...For sure, such therapies are still a few years away... but then approval from a phase III for mBC is 4 years away for ONCY.

And what would patiuents rather have, life extension of 10 months, or a cure. We still do not know whether addition of a CPI to the pela/pax doublet actually increases what was seen in IND-213.

Brad Thomson was on record stating that patients are living longer and longer, and this is why the H&N trial data was taking so long to mature... Then when it did..???

That was a Phase III trial, and it failed.

My point is, whilst we wait for more Phase II data, the field is moving... away from chemo + Pela + CPI, to Gene edited cures. What do you think the better investment is ?
<< Previous
Bullboard Posts
Next >>